 Shin Tsunekawa
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Neuropathies | 12 | 2022 | 36 | 2.340 |
Why?
| | Diabetes Mellitus, Experimental | 9 | 2022 | 192 | 1.720 |
Why?
| | Insulin-Secreting Cells | 8 | 2022 | 405 | 1.210 |
Why?
| | Hyperglycemia | 3 | 2015 | 184 | 0.900 |
Why?
| | Vital Statistics | 1 | 2018 | 3 | 0.780 |
Why?
| | Neural Conduction | 6 | 2020 | 67 | 0.770 |
Why?
| | Diabetes Mellitus | 4 | 2022 | 757 | 0.730 |
Why?
| | Insulin | 10 | 2022 | 1169 | 0.690 |
Why?
| | Gastric Inhibitory Polypeptide | 4 | 2018 | 10 | 0.610 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2011 | 56 | 0.570 |
Why?
| | Islets of Langerhans | 4 | 2022 | 539 | 0.570 |
Why?
| | Ganglia, Spinal | 5 | 2021 | 82 | 0.550 |
Why?
| | Carcinoma, Hepatocellular | 4 | 2015 | 319 | 0.510 |
Why?
| | Glucagon | 3 | 2022 | 117 | 0.510 |
Why?
| | Liver Neoplasms | 4 | 2015 | 634 | 0.480 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 409 | 0.470 |
Why?
| | Feedback, Physiological | 1 | 2011 | 66 | 0.450 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 155 | 0.430 |
Why?
| | Hepatocytes | 1 | 2011 | 125 | 0.430 |
Why?
| | Mice, Inbred C57BL | 14 | 2020 | 3180 | 0.430 |
Why?
| | Mice | 26 | 2022 | 11133 | 0.410 |
Why?
| | Quality Control | 1 | 2010 | 126 | 0.410 |
Why?
| | Antibodies, Antinuclear | 1 | 2010 | 88 | 0.400 |
Why?
| | Animals | 37 | 2022 | 26985 | 0.400 |
Why?
| | Liver | 10 | 2017 | 1246 | 0.390 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 338 | 0.390 |
Why?
| | Weight Gain | 3 | 2018 | 138 | 0.380 |
Why?
| | Calmodulin | 2 | 2007 | 49 | 0.380 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2020 | 544 | 0.370 |
Why?
| | Proglucagon | 3 | 2022 | 5 | 0.350 |
Why?
| | Venoms | 1 | 2007 | 12 | 0.340 |
Why?
| | Fibroblast Growth Factors | 3 | 2017 | 82 | 0.340 |
Why?
| | Stem Cells | 2 | 2020 | 353 | 0.340 |
Why?
| | Rats | 13 | 2022 | 4351 | 0.330 |
Why?
| | Peptides | 3 | 2022 | 640 | 0.310 |
Why?
| | Diet, High-Fat | 2 | 2018 | 105 | 0.310 |
Why?
| | Hypoglycemic Agents | 2 | 2019 | 380 | 0.300 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 1941 | 0.300 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 253 | 0.300 |
Why?
| | Nerve Growth Factors | 1 | 2005 | 68 | 0.290 |
Why?
| | Neuropeptides | 1 | 2005 | 116 | 0.290 |
Why?
| | Neurotransmitter Agents | 1 | 2005 | 112 | 0.280 |
Why?
| | Electroretinography | 2 | 2020 | 82 | 0.270 |
Why?
| | Neurons | 4 | 2021 | 1616 | 0.270 |
Why?
| | Diabetic Retinopathy | 2 | 2020 | 66 | 0.260 |
Why?
| | Insulin Resistance | 5 | 2019 | 388 | 0.260 |
Why?
| | Culture Media, Conditioned | 2 | 2020 | 104 | 0.240 |
Why?
| | Glucagon-Secreting Cells | 1 | 2022 | 26 | 0.240 |
Why?
| | Docosahexaenoic Acids | 1 | 2022 | 34 | 0.230 |
Why?
| | Dietary Carbohydrates | 2 | 2018 | 40 | 0.230 |
Why?
| | Nerve Fibers | 2 | 2019 | 44 | 0.230 |
Why?
| | Japan | 2 | 2019 | 292 | 0.230 |
Why?
| | Cell Line | 7 | 2021 | 2615 | 0.230 |
Why?
| | Apoptosis | 5 | 2021 | 1775 | 0.230 |
Why?
| | Pyruvaldehyde | 1 | 2021 | 8 | 0.230 |
Why?
| | Peripheral Nervous System | 1 | 2021 | 20 | 0.220 |
Why?
| | Tooth, Deciduous | 1 | 2020 | 3 | 0.220 |
Why?
| | Promoter Regions, Genetic | 3 | 2015 | 942 | 0.220 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 9 | 0.220 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2020 | 27 | 0.220 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 61 | 0.220 |
Why?
| | Thermosensing | 1 | 2019 | 2 | 0.210 |
Why?
| | Potassium Channels, Inwardly Rectifying | 2 | 2018 | 117 | 0.210 |
Why?
| | Arginase | 4 | 2001 | 16 | 0.210 |
Why?
| | Tomography, Optical Coherence | 1 | 2020 | 116 | 0.200 |
Why?
| | Spiro Compounds | 1 | 2019 | 25 | 0.200 |
Why?
| | Dental Pulp | 1 | 2019 | 4 | 0.200 |
Why?
| | Oxidative Stress | 2 | 2022 | 412 | 0.200 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 44 | 0.200 |
Why?
| | Pyrazines | 1 | 2019 | 86 | 0.200 |
Why?
| | Electrodiagnosis | 1 | 2019 | 8 | 0.200 |
Why?
| | Rats, Wistar | 4 | 2019 | 318 | 0.200 |
Why?
| | Exocytosis | 1 | 2019 | 109 | 0.190 |
Why?
| | Cyclin D2 | 1 | 2018 | 18 | 0.190 |
Why?
| | Mice, Knockout | 6 | 2020 | 1953 | 0.190 |
Why?
| | Retina | 1 | 2020 | 210 | 0.190 |
Why?
| | Bone Morphogenetic Protein 4 | 2 | 2015 | 18 | 0.180 |
Why?
| | Male | 22 | 2020 | 41899 | 0.180 |
Why?
| | Glucose | 3 | 2018 | 625 | 0.180 |
Why?
| | Cell Nucleus | 3 | 2019 | 589 | 0.180 |
Why?
| | Organ Specificity | 3 | 2017 | 260 | 0.180 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 134 | 0.180 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2020 | 1286 | 0.180 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 190 | 0.180 |
Why?
| | Dietary Sucrose | 1 | 2017 | 13 | 0.180 |
Why?
| | Atherosclerosis | 1 | 2020 | 234 | 0.180 |
Why?
| | Cause of Death | 1 | 2018 | 273 | 0.170 |
Why?
| | Adenosine Triphosphate | 1 | 2018 | 310 | 0.170 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2017 | 27 | 0.170 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 72 | 0.170 |
Why?
| | Myoblasts | 1 | 2017 | 29 | 0.170 |
Why?
| | Dietary Fats | 1 | 2018 | 166 | 0.170 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2017 | 50 | 0.170 |
Why?
| | Energy Metabolism | 3 | 2017 | 265 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2007 | 1553 | 0.160 |
Why?
| | Autoantigens | 3 | 2002 | 135 | 0.160 |
Why?
| | Glycolysis | 1 | 2017 | 128 | 0.160 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 674 | 0.160 |
Why?
| | Glucose Tolerance Test | 4 | 2019 | 241 | 0.150 |
Why?
| | Clostridium | 1 | 2015 | 37 | 0.150 |
Why?
| | Palmitic Acid | 1 | 2015 | 36 | 0.150 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2014 | 4 | 0.140 |
Why?
| | Liver Diseases | 4 | 2001 | 227 | 0.140 |
Why?
| | KATP Channels | 1 | 2014 | 19 | 0.140 |
Why?
| | Diabetic Foot | 1 | 2014 | 14 | 0.140 |
Why?
| | Roseolovirus Infections | 1 | 2014 | 7 | 0.140 |
Why?
| | Tissue Culture Techniques | 2 | 2011 | 78 | 0.140 |
Why?
| | Herpesvirus 6, Human | 1 | 2014 | 19 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 376 | 0.140 |
Why?
| | Fatty Liver | 1 | 2015 | 123 | 0.140 |
Why?
| | Adipocytes, White | 1 | 2013 | 3 | 0.130 |
Why?
| | Humans | 25 | 2022 | 83447 | 0.130 |
Why?
| | Red-Cell Aplasia, Pure | 1 | 2013 | 5 | 0.130 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2014 | 53 | 0.130 |
Why?
| | RNA, Messenger | 4 | 2020 | 1996 | 0.130 |
Why?
| | Keratinocytes | 1 | 2014 | 134 | 0.130 |
Why?
| | Steroids | 1 | 2014 | 175 | 0.130 |
Why?
| | Gastrointestinal Tract | 1 | 2015 | 191 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2020 | 2969 | 0.120 |
Why?
| | Neural Crest | 1 | 2012 | 25 | 0.120 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1212 | 0.120 |
Why?
| | Cell Communication | 1 | 2013 | 190 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 655 | 0.120 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 164 | 0.120 |
Why?
| | Wound Healing | 2 | 2014 | 348 | 0.120 |
Why?
| | Blood Glucose | 3 | 2019 | 901 | 0.120 |
Why?
| | Calcineurin | 1 | 2011 | 17 | 0.120 |
Why?
| | Peptide Fragments | 2 | 2012 | 480 | 0.120 |
Why?
| | NFATC Transcription Factors | 1 | 2011 | 28 | 0.120 |
Why?
| | Diet | 1 | 2015 | 451 | 0.120 |
Why?
| | Response Elements | 1 | 2011 | 66 | 0.110 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 89 | 0.110 |
Why?
| | Mesenchymal Stem Cells | 1 | 2014 | 291 | 0.110 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2022 | 42 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2015 | 1474 | 0.110 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2020 | 42 | 0.110 |
Why?
| | Calcium Signaling | 1 | 2011 | 132 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2013 | 694 | 0.110 |
Why?
| | DNA Methylation | 1 | 2015 | 577 | 0.100 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 41 | 0.100 |
Why?
| | Macrophages | 1 | 2013 | 556 | 0.100 |
Why?
| | Protein Transport | 1 | 2011 | 420 | 0.100 |
Why?
| | Cytodiagnosis | 3 | 1985 | 43 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1167 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2002 | 397 | 0.100 |
Why?
| | Cell Survival | 3 | 2021 | 1012 | 0.100 |
Why?
| | Autoantibodies | 2 | 2001 | 257 | 0.100 |
Why?
| | Creatine Kinase | 2 | 1998 | 55 | 0.090 |
Why?
| | Neurites | 2 | 2021 | 39 | 0.090 |
Why?
| | Receptors, Glucagon | 2 | 2020 | 11 | 0.090 |
Why?
| | Transcription Factor CHOP | 1 | 2007 | 17 | 0.090 |
Why?
| | Signal Transduction | 2 | 2022 | 3301 | 0.090 |
Why?
| | Middle Aged | 10 | 2020 | 25596 | 0.080 |
Why?
| | Molecular Chaperones | 1 | 2007 | 114 | 0.080 |
Why?
| | United States | 1 | 2018 | 6316 | 0.080 |
Why?
| | Receptors, Gastrointestinal Hormone | 2 | 2018 | 5 | 0.080 |
Why?
| | Heat-Shock Proteins | 1 | 2007 | 178 | 0.080 |
Why?
| | Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2005 | 2 | 0.080 |
Why?
| | Streptozocin | 2 | 2016 | 56 | 0.070 |
Why?
| | Mice, Inbred ICR | 1 | 2005 | 70 | 0.070 |
Why?
| | Cyclic AMP | 2 | 2019 | 280 | 0.070 |
Why?
| | Benzoates | 1 | 2005 | 47 | 0.070 |
Why?
| | Valine | 1 | 2005 | 77 | 0.070 |
Why?
| | Tetrazoles | 1 | 2005 | 54 | 0.070 |
Why?
| | Glucose Intolerance | 2 | 2018 | 101 | 0.070 |
Why?
| | Nuclear Proteins | 2 | 2017 | 697 | 0.070 |
Why?
| | Stress, Physiological | 1 | 2007 | 247 | 0.070 |
Why?
| | Adult | 5 | 2020 | 25995 | 0.070 |
Why?
| | Diabetic Angiopathies | 1 | 2005 | 69 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 924 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2020 | 1778 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 99 | 0.070 |
Why?
| | Female | 12 | 2020 | 44784 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2005 | 137 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2674 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2017 | 1064 | 0.060 |
Why?
| | tert-Butylhydroperoxide | 1 | 2022 | 2 | 0.060 |
Why?
| | NAD | 1 | 2022 | 74 | 0.060 |
Why?
| | Clonal Deletion | 1 | 2002 | 25 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2002 | 74 | 0.060 |
Why?
| | Pancreatic Hormones | 1 | 2022 | 14 | 0.060 |
Why?
| | Schwann Cells | 1 | 2022 | 34 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2022 | 181 | 0.060 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2022 | 62 | 0.060 |
Why?
| | Retinal Photoreceptor Cell Outer Segment | 1 | 2020 | 3 | 0.060 |
Why?
| | Retinal Photoreceptor Cell Inner Segment | 1 | 2020 | 4 | 0.060 |
Why?
| | Retinal Pigment Epithelium | 1 | 2020 | 5 | 0.060 |
Why?
| | Muscle, Skeletal | 2 | 2017 | 451 | 0.060 |
Why?
| | Tooth Exfoliation | 1 | 2020 | 2 | 0.060 |
Why?
| | Fovea Centralis | 1 | 2020 | 19 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2020 | 27 | 0.060 |
Why?
| | Peripheral Nerves | 1 | 2020 | 33 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2020 | 2299 | 0.060 |
Why?
| | Thymus Gland | 1 | 2002 | 224 | 0.050 |
Why?
| | Aged | 5 | 2020 | 18508 | 0.050 |
Why?
| | Cell Death | 1 | 2022 | 273 | 0.050 |
Why?
| | Liver Transplantation | 2 | 2001 | 1249 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2020 | 30 | 0.050 |
Why?
| | Hyperalgesia | 1 | 2020 | 18 | 0.050 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2021 | 98 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2020 | 62 | 0.050 |
Why?
| | Cell Separation | 1 | 2020 | 215 | 0.050 |
Why?
| | Aldehyde Reductase | 1 | 2019 | 12 | 0.050 |
Why?
| | Gene Expression | 1 | 2005 | 1331 | 0.050 |
Why?
| | Electromyography | 1 | 2020 | 183 | 0.050 |
Why?
| | Autophagy | 1 | 2022 | 164 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2020 | 136 | 0.050 |
Why?
| | Ribonucleoprotein, U1 Small Nuclear | 1 | 1999 | 2 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 395 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2001 | 285 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2019 | 36 | 0.050 |
Why?
| | Epidermis | 1 | 2019 | 98 | 0.050 |
Why?
| | Calcitonin | 1 | 2019 | 44 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2020 | 6577 | 0.050 |
Why?
| | Phosphocreatine | 1 | 1998 | 12 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2002 | 347 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 182 | 0.050 |
Why?
| | Substance P | 1 | 2019 | 60 | 0.050 |
Why?
| | Motor Skills | 1 | 2019 | 77 | 0.050 |
Why?
| | Cell Movement | 2 | 2020 | 745 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1758 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 806 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2002 | 405 | 0.050 |
Why?
| | Neuroprotective Agents | 1 | 2019 | 94 | 0.050 |
Why?
| | ROC Curve | 1 | 2020 | 761 | 0.050 |
Why?
| | Transcription Factors | 2 | 2017 | 1517 | 0.050 |
Why?
| | Ultrasonography | 1 | 2020 | 696 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 459 | 0.040 |
Why?
| | Patch-Clamp Techniques | 1 | 2019 | 454 | 0.040 |
Why?
| | Starch | 1 | 2017 | 10 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2019 | 186 | 0.040 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2019 | 174 | 0.040 |
Why?
| | Adipose Tissue, White | 1 | 2017 | 17 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 24 | 0.040 |
Why?
| | Antioxidants | 1 | 2019 | 231 | 0.040 |
Why?
| | Graft Survival | 1 | 2001 | 884 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 47 | 0.040 |
Why?
| | Hexokinase | 1 | 2017 | 19 | 0.040 |
Why?
| | Oxyhemoglobins | 1 | 1996 | 31 | 0.040 |
Why?
| | Enzyme Induction | 1 | 2017 | 93 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 43 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 1999 | 227 | 0.040 |
Why?
| | Mitochondria | 1 | 2021 | 532 | 0.040 |
Why?
| | Endotoxins | 1 | 1996 | 38 | 0.040 |
Why?
| | Models, Statistical | 1 | 2020 | 580 | 0.040 |
Why?
| | Erythrocytes | 2 | 2001 | 266 | 0.040 |
Why?
| | Transcription Factor Pit-1 | 1 | 2015 | 6 | 0.040 |
Why?
| | Hypertension | 1 | 2005 | 1209 | 0.040 |
Why?
| | LIM-Homeodomain Proteins | 1 | 2015 | 22 | 0.040 |
Why?
| | Ectoderm | 1 | 2015 | 33 | 0.040 |
Why?
| | Hepatectomy | 1 | 1996 | 154 | 0.040 |
Why?
| | Paired Box Transcription Factors | 1 | 2015 | 51 | 0.040 |
Why?
| | Rats, Zucker | 1 | 2015 | 39 | 0.040 |
Why?
| | Mice, Inbred BALB C | 3 | 2002 | 1073 | 0.040 |
Why?
| | Graft Rejection | 1 | 2001 | 1110 | 0.040 |
Why?
| | Phlorhizin | 1 | 2014 | 3 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 3877 | 0.040 |
Why?
| | Diazoxide | 1 | 2014 | 18 | 0.040 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 1994 | 4 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 1825 | 0.030 |
Why?
| | Lung Diseases | 1 | 1996 | 268 | 0.030 |
Why?
| | Growth Substances | 1 | 1994 | 88 | 0.030 |
Why?
| | Foot | 1 | 2014 | 54 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 100 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2014 | 62 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1994 | 68 | 0.030 |
Why?
| | Eye Proteins | 1 | 2015 | 130 | 0.030 |
Why?
| | Adipokines | 1 | 2013 | 22 | 0.030 |
Why?
| | 3T3-L1 Cells | 1 | 2013 | 40 | 0.030 |
Why?
| | Macrophage Activation | 1 | 2013 | 39 | 0.030 |
Why?
| | Paracrine Communication | 1 | 2013 | 25 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2013 | 159 | 0.030 |
Why?
| | Immunomodulation | 1 | 2013 | 57 | 0.030 |
Why?
| | Prognosis | 2 | 2019 | 3709 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 158 | 0.030 |
Why?
| | Receptor, Nerve Growth Factor | 1 | 2012 | 6 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 29 | 0.030 |
Why?
| | Nerve Growth Factor | 1 | 2012 | 26 | 0.030 |
Why?
| | Sciatic Nerve | 1 | 2012 | 35 | 0.030 |
Why?
| | Incretins | 1 | 2012 | 15 | 0.030 |
Why?
| | Gene Silencing | 1 | 2013 | 183 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 132 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1613 | 0.030 |
Why?
| | Mass Screening | 2 | 1989 | 623 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2013 | 168 | 0.030 |
Why?
| | Ovalbumin | 2 | 2002 | 112 | 0.030 |
Why?
| | Child | 2 | 2020 | 6768 | 0.030 |
Why?
| | Gene Deletion | 1 | 2012 | 346 | 0.030 |
Why?
| | Immunization, Secondary | 2 | 2002 | 27 | 0.030 |
Why?
| | Cell Lineage | 1 | 2012 | 288 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2015 | 546 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 1370 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 383 | 0.030 |
Why?
| | Intestines | 1 | 1994 | 424 | 0.030 |
Why?
| | Skin | 1 | 2014 | 560 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2012 | 726 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 232 | 0.030 |
Why?
| | Homeostasis | 1 | 2012 | 397 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 1991 | 115 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2017 | 1207 | 0.030 |
Why?
| | Quality of Life | 1 | 1996 | 1369 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1823 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 750 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1989 | 249 | 0.020 |
Why?
| | Reference Values | 2 | 2001 | 702 | 0.020 |
Why?
| | Obesity | 1 | 2013 | 966 | 0.020 |
Why?
| | Oxygen Consumption | 2 | 1996 | 250 | 0.020 |
Why?
| | Pattern Recognition, Automated | 2 | 1985 | 225 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2005 | 69 | 0.020 |
Why?
| | Probability | 1 | 1985 | 358 | 0.020 |
Why?
| | Colonic Neoplasms | 2 | 2001 | 561 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 250 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1989 | 1179 | 0.020 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 20 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1989 | 1036 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2002 | 124 | 0.010 |
Why?
| | Convalescence | 1 | 2001 | 10 | 0.010 |
Why?
| | Clonal Anergy | 1 | 2002 | 36 | 0.010 |
Why?
| | Hepatitis | 1 | 2001 | 32 | 0.010 |
Why?
| | Carbon Tetrachloride Poisoning | 1 | 2001 | 3 | 0.010 |
Why?
| | Calibration | 1 | 2001 | 104 | 0.010 |
Why?
| | Cholangiocarcinoma | 1 | 2001 | 57 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 7905 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 217 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 2001 | 155 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 299 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 831 | 0.010 |
Why?
| | Self Tolerance | 1 | 1999 | 23 | 0.010 |
Why?
| | Acute Disease | 1 | 2001 | 862 | 0.010 |
Why?
| | Neoplasms | 3 | 1985 | 2692 | 0.010 |
Why?
| | Galactosamine | 1 | 1998 | 8 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1999 | 178 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1998 | 71 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1998 | 78 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2001 | 482 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 1999 | 168 | 0.010 |
Why?
| | Transgenes | 1 | 1999 | 182 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1200 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 1999 | 72 | 0.010 |
Why?
| | Necrosis | 1 | 1998 | 208 | 0.010 |
Why?
| | Rabbits | 1 | 1999 | 716 | 0.010 |
Why?
| | Isoenzymes | 1 | 1998 | 276 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1998 | 277 | 0.010 |
Why?
| | Sulfur Dioxide | 1 | 1996 | 1 | 0.010 |
Why?
| | Hepatic Veins | 1 | 1996 | 25 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 1996 | 27 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1996 | 54 | 0.010 |
Why?
| | Oxidative Phosphorylation | 1 | 1996 | 44 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1996 | 70 | 0.010 |
Why?
| | Adenine Nucleotides | 1 | 1996 | 61 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2001 | 2080 | 0.010 |
Why?
| | Neoplastic Cells, Circulating | 1 | 1996 | 71 | 0.010 |
Why?
| | Portal Vein | 1 | 1996 | 123 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 434 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 1996 | 144 | 0.010 |
Why?
| | Sepsis | 1 | 1998 | 299 | 0.010 |
Why?
| | Fibroblast Growth Factor 10 | 1 | 1994 | 6 | 0.010 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 1994 | 9 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1994 | 272 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2001 | 1524 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1622 | 0.010 |
Why?
| | Gallbladder Neoplasms | 1 | 1993 | 28 | 0.010 |
Why?
| | Hemolysis | 1 | 1993 | 62 | 0.010 |
Why?
| | Epithelium | 1 | 1994 | 321 | 0.010 |
Why?
| | Cytokines | 1 | 1996 | 753 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 1994 | 286 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1999 | 1288 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1994 | 1088 | 0.010 |
Why?
| | Survival Rate | 1 | 1996 | 1919 | 0.010 |
Why?
| | Adolescent | 2 | 1996 | 9140 | 0.010 |
Why?
| | Computers | 2 | 1982 | 109 | 0.010 |
Why?
| | Molecular Weight | 1 | 1991 | 372 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1991 | 302 | 0.010 |
Why?
| | Chickens | 1 | 1991 | 232 | 0.010 |
Why?
| | Calpain | 1 | 1991 | 111 | 0.010 |
Why?
| | Epithelial Cells | 1 | 1994 | 627 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1996 | 1187 | 0.010 |
Why?
| | Brain | 1 | 1998 | 2160 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1996 | 2569 | 0.000 |
Why?
| | Magnetic Resonance Imaging | 1 | 1996 | 3267 | 0.000 |
Why?
|
|
Tsunekawa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|